Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model
about
Substrate binding process and mechanistic functioning of type 1 11β-hydroxysteroid dehydrogenase from enhanced sampling methods.Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases.11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery.New perspectives on the development of antiobesity drugs.Mouse 11β-hydroxysteroid dehydrogenase type 2 for human application: homology modeling, structural analysis and ligand-receptor interaction.Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids.On-column ligand exchange for structure-based drug design: a case study with human 11β-hydroxysteroid dehydrogenase type 1.Metabolism-guided drug designProtein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins
P2860
Q34038269-0054EDF2-3E82-4656-B8A8-C1933A910775Q34162283-0CFDA0C2-5D49-4ACF-AFF1-577B69D6AEC8Q34253331-0E6880D0-D9A4-438E-96A0-285387347DCEQ34316507-926B09E0-04B3-4201-B61E-F57E6F3D9AA4Q36211201-F955E3C9-0BEC-4A21-9ACD-6186D87DE613Q36434907-B293A3F6-0E9A-4A1C-A9FE-D6D81A8681B8Q37655884-9595F1D0-CE2F-44D8-89F3-39E0F594CF05Q37859010-E419D53F-5336-48E9-A513-7494D78E52A7Q38397340-24A0EB1B-C861-4022-8297-918F5D77B44BQ39739852-0DB5CAC7-9908-4585-9FF6-A74F1CB84501Q39777340-72839941-0AD1-4387-87B9-824F848429B0Q40666632-932EFBF4-D5E8-4018-8CAE-72598D83AD36Q41844272-FC6451B1-9E87-4346-ADBF-FE1A4A8E7D33Q56115898-7BF13BC6-EA85-4F75-B5BC-0B4173B76D9AQ56999539-4798C8FF-CD6E-42A1-8A30-BDA3D8197050
P2860
Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@ast
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@en
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@nl
type
label
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@ast
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@en
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@nl
prefLabel
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@ast
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@en
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@nl
P2093
P356
P1476
Efficacious 11beta-hydroxyster ...... et-induced obesity mouse model
@en
P2093
Ariful Qadri
Christian E Johnson
Darrell Panza
Eddine Saiah
Eva Chenail
Huan-Qiu Li
James F Tobin
Jason Xiang
Kristine Svenson
P304
P356
10.1021/JM900639U
P407
P577
2009-09-10T00:00:00Z